Par Drugs Total Debt vs. Price To Book
| PAR Stock | 290.40 11.35 4.07% |
For Par Drugs profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Par Drugs to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Par Drugs And utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Par Drugs's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Par Drugs And over time as well as its relative position and ranking within its peers.
Par |
Par Drugs And Price To Book vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Par Drugs's current stock value. Our valuation model uses many indicators to compare Par Drugs value to that of its competitors to determine the firm's financial worth. Par Drugs And is rated top company in total debt category among its peers. It also is considered to be number one stock in price to book category among its peers . The ratio of Total Debt to Price To Book for Par Drugs And is about 45,029,307 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Par Drugs' earnings, one of the primary drivers of an investment's value.Par Total Debt vs. Competition
Par Drugs And is rated top company in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 398.01 Billion. Par Drugs adds roughly 159.79 Million in total debt claiming only tiny portion of equities under Health Care industry.
Par Price To Book vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Par Drugs |
| = | 159.79 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Par Drugs |
| = | 3.55 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Par Price To Book Comparison
Par Drugs is currently under evaluation in price to book category among its peers.
Par Drugs Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Par Drugs, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Par Drugs will eventually generate negative long term returns. The profitability progress is the general direction of Par Drugs' change in net profit over the period of time. It can combine multiple indicators of Par Drugs, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 1.2 M | 1.3 M | |
| Operating Income | 551.6 M | 579.2 M | |
| Income Before Tax | 195.2 M | 204.9 M | |
| Total Other Income Expense Net | -356.4 M | -338.6 M | |
| Net Income | 145 M | 88.5 M | |
| Income Tax Expense | 50.2 M | 52.7 M | |
| Net Interest Income | -1.1 M | -1.1 M | |
| Interest Income | 826.9 K | 1.1 M | |
| Net Income From Continuing Ops | 145 M | 87 M | |
| Net Income Applicable To Common Shares | 106 M | 65.2 M | |
| Change To Netincome | 4.9 M | 5.6 M |
Par Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Par Drugs. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Par Drugs position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Par Drugs' important profitability drivers and their relationship over time.
Use Par Drugs in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Par Drugs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Par Drugs will appreciate offsetting losses from the drop in the long position's value.Par Drugs Pair Trading
Par Drugs And Pair Trading Analysis
The ability to find closely correlated positions to Par Drugs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Par Drugs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Par Drugs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Par Drugs And to buy it.
The correlation of Par Drugs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Par Drugs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Par Drugs And moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Par Drugs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Par Drugs position
In addition to having Par Drugs in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Construction Materials Thematic Idea Now
Construction Materials
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Construction Materials theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Construction Materials Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Par Stock
To fully project Par Drugs' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Par Drugs And at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Par Drugs' income statement, its balance sheet, and the statement of cash flows.